Immune Globulin · HUMAN IMMUNOGLOBULIN G 100 mg/mL · Solution · Intravenous · Pfizer Laboratories Div Pfizer Inc
NDC 00069-6237-02 · 1 BOTTLE, GLASS in 1 CARTON / 200 mL in 1 BOTTLE, GLASS · BLA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Put together: worth watching — several of the pressures that precede supply trouble are present at once.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Matched to CMS's representative package for this drug (NDC 68982-0850-01) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
There's no legal definition — it meets 2 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Pfizer Laboratories Div Pfizer Inc | HUMAN IMMUNOGLOBULIN G 100 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Pfizer Laboratories Div Pfizer Inc | HUMAN IMMUNOGLOBULIN G 50 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Octapharma USA Inc | HUMAN IMMUNOGLOBULIN G 100 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Octapharma USA Inc | HUMAN IMMUNOGLOBULIN G 50 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Octagam Immune Globulin (Human) — NDC 00069-6237-02," retrieved September 3, 2026, https://drugdashboards.com/drug/00069623702.
Free to cite with attribution — see how the data is put together.